Publisher retracts paper with ethics committee discrepancy after question from Retraction Watch

Dove, a publisher owned by Taylor & Francis, has retracted a paper published last year after a Retraction Watch reader pointed out that the authors’ statements on ethical approval made no sense. Dove’s Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy published the article, “Serum Human Epididymis Protein 4 is a Potential Biomarker for Early … Continue reading Publisher retracts paper with ethics committee discrepancy after question from Retraction Watch

Pro-tip: When claiming to use a dataset, make sure it collects what you say it does

Irish eyes most definitely were not smiling on three papers that purported to contain data from a national repository from the Emerald Isle.  The articles, which appeared in a trio of journals from Dove Medical Press — part of Taylor & Francis — were written by various researchers at Nanchang University, in China.  Two of … Continue reading Pro-tip: When claiming to use a dataset, make sure it collects what you say it does

Publisher won’t retract most papers by chemist editor-in-chief who left university post under a cloud

The retractions appear to be trickling in for Thomas Webster, a once-prominent chemistry researcher who left his post at Northeastern University after nearly 70 of his papers were flagged on PubPeer for concerns about the data in the studies.  But while the publisher of a journal he co-founded — and left earlier this year — … Continue reading Publisher won’t retract most papers by chemist editor-in-chief who left university post under a cloud

Supplement-selling doctor who ran afoul of FDA and state medical board up to 20 retractions

Dove Press, which late last year retracted more than a dozen articles by a U.S. physician who appears to have used the articles and other publications as marketing material for dietary supplements he sold, has pulled six more of his papers.  The new retractions make 20 removals by Dove — a unit of Taylor & … Continue reading Supplement-selling doctor who ran afoul of FDA and state medical board up to 20 retractions

Publisher retracts 14 papers by doctor who ran afoul of U.S. FDA for marketing supplements

Dove Press last week retracted 14 papers by Marty Hinz, a Minnesota doctor who caught the attention of the U.S. FDA years ago for hyping supplements sold by a company he once owned. The 14 articles — on the use of supplements to treat conditions ranging from Crohn’s disease to Parkinson’s disease — were among … Continue reading Publisher retracts 14 papers by doctor who ran afoul of U.S. FDA for marketing supplements

‘An isolated incident’: Should reviewers check references?

Peer reviewers are supposed to be experts in their fields, competent enough at least to spot methodological errors, wayward conclusions and implausible findings. But checking references? Apparently, not so much.  A journal about academic medicine has retracted a 2020 article because its reviewers and editors didn’t bother to confirm that the references said what the … Continue reading ‘An isolated incident’: Should reviewers check references?

Publisher retracts paper when authors try publishing it again in another of its journals

Pro-tip: If you’re going to try to publish the same paper twice, don’t submit the duplicated version to a journal from the same publisher where you published the original — especially if you plan to monkey with the data. Well, don’t try to publish the same paper twice, nor monkey with data, period. But you’ll … Continue reading Publisher retracts paper when authors try publishing it again in another of its journals

Journal flags paper on painkiller for misused trial registry record

A pain journal has expressed concern over a 2018 paper by a group of researchers in China after a reader alerted the publication to problems with the article, including previously-reported data and a bogus trial registry record.  The article, “Population pharmacokinetic modeling of flurbiprofen, the active metabolite of flurbiprofen axetil, in Chinese patients with postoperative … Continue reading Journal flags paper on painkiller for misused trial registry record

Conflicts of disinterest: Why does it take a publisher 18 months, and counting, to correct papers?

On February 23, 2018, Stephen Barrett — a physician in the United States perhaps best known for his work at Quackwatch — sent Dove Press this message: I believe you have published 20 articles in 6 of your journals in which the lead author did not make a full conflict-of-interest disclosure. Please email me directly … Continue reading Conflicts of disinterest: Why does it take a publisher 18 months, and counting, to correct papers?

Caught Our Notice: Wait…we wrote WHAT paper?

Title: Assessment of coronary heart diseases in diabetics in al-Madinah al-Munawarah What Caught Our Notice: We’ve seen researchers dinged for adding authors to papers who didn’t participate in the research, but it’s rare to have a notice say co-author signatures were forged. In a recent retraction, the first two authors said the signatures on the the […]

The post Caught Our Notice: Wait…we wrote WHAT paper? appeared first on Retraction Watch.